ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

Fusion Antibodies Takeover Rumours (FAB)

Fusion Antibodies Chart

Fusion Antibodies Takeover Price

Fusion Antibodies Takeover Forum Posts

19-01-2024
20p (market cap £12m) doesn't seem an unreasonable valuation to me at this stage, and then grow from there as news flow continues in 2024, especially with NCI updates etc. If they need to raise a modest amount of cash for working capital at much higher valuations, I don't think any reasonable holder will object. As the CEO has highlighted, once NCI endorsement/validation has been achieved in the next 12-18 months, the company becomes a glaring takeover target. £100m (150p per share) would be a very achievable valuation, quite possibly substantially more. £100m is small change to a major pharma! While there's no doubt it's a risky AIM smallcap, on the positive side there seems to be little downside at a market cap of £4m? Good luck all, no advice intended etc